source
- Biotech firm Biogen secures Chinese approval for felzartamab in second-line multiple myelomaBiogen announced that its monoclonal antibody felzartamab has received regulatory clearance in China for use in patients with multiple myeloma who have already received first-line therapy. The app…
- Two undisclosed gene-therapy deaths raise doubts about China's fast-track trial pathwayTwo recent deaths in China’s early‑stage gene‑therapy trials have drawn international attention. Both patients suffered severe immune reactions after receiving high‑dose viral vector treatments, an…